The Risk of Arterial Thrombosis in Patients With Chronic Myeloid Leukemia Treated With Second and Third Generation BCR-ABL Tyrosine Kinase Inhibitors May Be Explained by Their Impact on Endothelial Cells: An In-Vitro Study

BCR-ABL tyrosine kinase inhibitors (TKIs) revolutionized the treatment of chronic myeloid leukemia, inducing deep molecular responses, largely improving patient survival and rendering treatment-free remission possible. However, three of the five BCR-ABL TKIs, dasatinib, nilotinib, and ponatinib, inc...

Descripción completa

Detalles Bibliográficos
Autores principales: Haguet, Hélène, Bouvy, Céline, Delvigne, Anne-Sophie, Modaffari, Elise, Wannez, Adeline, Sonveaux, Pierre, Dogné, Jean-Michel, Douxfils, Jonathan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7350860/
https://www.ncbi.nlm.nih.gov/pubmed/32719607
http://dx.doi.org/10.3389/fphar.2020.01007

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7350860/
https://www.ncbi.nlm.nih.gov/pubmed/32719607
http://dx.doi.org/10.3389/fphar.2020.01007

Ejemplares similares